EGFR and non-small cell lung carcinoma: Therefore, erlotinib and other EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib, afatinib, and osimertinib are the first-line therapies to treat EGFR mutation positive NSCLC in stage IIIB and IV [3].